Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMIT: Sequential Gemcitabine and Jelmyto for Upper Tract Urothelial Carcinoma
NCT06822010Phase 2Recruiting
- Sponsor
- Rutgers University
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, mitomycin c + TC-3 gel in upper tract urothelial carcinoma (UTUC), sponsored by Rutgers University. Started Mar 2026; status: recruiting.
02
Drugs
gemcitabinemitomycin c + TC-3 gel
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT06822010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822010.